Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunogenic composition

An immunogenic, genomic technology for vaccine applications

Pending Publication Date: 2022-05-13
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the results demonstrate that reactogenicity can be altered by lipid A engineering, growth defects of the strains are a major obstacle to the use of these strains in vaccine production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogenic composition
  • Immunogenic composition
  • Immunogenic composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0274] Embodiment 1. A recombinant Bordetella pertussis comprising:

[0275] (i) at least one genomic LpxA gene encoding an LpxA protein, wherein the LpxA protein comprises a mutation at position 170 and / or a mutation at position 229 relative to SEQ ID NO: 1; and / or

[0276] (ii) Genomic insertion of at least one heterologous LpxD gene.

Embodiment approach 2

[0277] Embodiment 2. The recombinant Bordetella pertussis of embodiment 1 comprising at least one genomic LpxA gene encoding an LpxA protein, wherein the LpxA protein comprises a substitution relative to position 170 of SEQ ID NO: 1 and / or a permutation of 229 bits.

Embodiment approach 3

[0278] Embodiment 3. The recombinant Bordetella pertussis of embodiment 1 or 2, wherein the LpxA protein comprises a serine residue at position 170 and / or an alanine at position 229 relative to SEQ ID NO: 1 Residues.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
adsorption capacityaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to bacterial strains, in particular for use in the field of vaccines, in particular in the prevention or treatment of infections caused by Bordetella bacteria.

Description

technical field [0001] The present invention relates to the field of vaccines, in particular to the prevention or treatment of infections caused by bacteria of the genus Bordetella, in particular Bordetella pertussis. Background technique [0002] Pertussis, caused by the bacterium Bordetella pertussis, is a highly contagious airway infection. Acute infection can cause severe disease characterized by respiratory failure, pulmonary hypertension, leukocytosis, and death. Pertussis is a vaccine-preventable disease, and acellular pertussis (aP) or whole-cell pertussis (wP) vaccines are used worldwide. However, the disease persists in vaccinated populations, and epidemiological data report an increase in the incidence of pertussis worldwide in recent years. [0003] Several hypotheses have been postulated, including the evolution of pertussis strains and the shortened duration of protection of aP vaccines compared to wP vaccines. One area of ​​research aimed at controlling the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/099
CPCC07K14/235A61K39/099C12N1/20Y02A50/30C12N15/74A61P31/04A61K2039/552
Inventor N·I·德沃斯S·C·西蒙斯
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com